Finn's Take· TL;DRCVS Health has announced plans to split into two companies — one housing its insurance arm Aetna and pharmacy benefit manager Caremark, and one with its 9,000 retail pharmacies — in what would be one of the largest corporate breakups in history. The split comes a decade after the $78 billion merger that combined CVS with Aetna, and marks a sweeping reversal of the vertical integration strategy that defined the healthcare industry for years.
On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The company expects to complete the separation in the first half of 2028, subject to final board approval and other conditions.
The healthcare solutions company, which will use the CVS Health name during the transition, would include health insurer Aetna, pharmacy benefit manager CVS Caremark, and specialty pharmacy business CVS Specialty. It would also retain Oak Street Health and Signify Health.
The second company, to be named CVS Pharmacy, would operate 9,000 retail pharmacies, along with the mail-order pharmacy business, MinuteClinic, and the Health100 technology services business. CVS Pharmacy will be led by Prem Shah, currently group president, while CVS Health keeps Aetna, Caremark, Oak Street Health, Signify Health, and specialty pharmacy under chief executive David Joyner. CVS Health shareholders would own shares in both companies after the split.
CVS shares closed down 12.5%, slashing nearly $15 billion in market value. The market's reaction was swift and punishing, even though the announcement came alongside a strong quarterly earnings report. UBS analyst Kevin Caliendo said, "CVS shares are weak today despite very strong Q3 operating results because the announced split of the company came as a surprise, and is perceived as happening as a defensive move against regulation rather than an offensive move."
Barclays analyst Andrew Mok cited a lack of financial detail around the breakup as a primary investor concern, adding that when CVS bought Caremark 20 years ago, it said it would result in synergies of at least $500 million. RBC's analyst also raised questions about how the split could impact Aetna's Medicare Advantage quality ratings, which determine whether health plans qualify for bonus payments from the government. Retail pharmacists have played a role in engaging Aetna members, and a separation could complicate that relationship.
The economics of the businesses have changed: CVS's retail pharmacy business has become more consistently profitable, while Aetna has improved its performance despite persistently high medical costs in Medicare Advantage plans. CEO David Joyner told CNBC that back in 2024, the company was "in a turnaround" without the flexibility, cash, or business performance to execute a split.
Regulatory pressure isn't the reason for the split, according to Joyner. Instead, the CEO characterized the breakup as the logical next step in CVS's "evolution" — one that will create two stronger and more streamlined organizations that can tailor strategies and investments to their specific needs. CVS Health said it expects both companies to have investment-grade credit ratings and generate strong free cash flow.
The notion that CVS would split its operations effectively unwinds one of the most high-profile healthcare mergers in recent memory, and would mark the end of an era in which healthcare conglomerates could grow unchecked. Whether the two leaner, more focused companies can outperform the sprawling empire they're replacing is a question investors and patients alike will be watching closely between now and 2028.